New incident report
Incident Report Number: 2024-1303
Registrant Reference Number: 2024-US-0025659
Registrant Name (Full Legal Name no abbreviations): Neogen Corporation
Address: 620 Lesher Place
City: Lansing
Prov / State: MI
Country: United States
Postal Code: 48912
Human
Country: UNITED STATES
Prov / State: CALIFORNIA
PMRA Registration No. PMRA Submission No. EPA Registration No. 61282-12
Product Name: Ramik Bars
Bait
Unknown
Unknown
Other
Sex: Male
Age: >64 yrs / > 64 ans
System
Unknown / Inconnu
Yes
Yes
Unknown
Unknown
Other
None
Skin
Unknown / Inconnu
>2 hrs <=8 hrs / > 2 h < = 8 h
On 30-Jan-2024, a 70 year old, 212 pound, male human, with concomitant medical conditions of hypertension, high cholesterol, and depression, was exposed to an unknown amount of Ramik Bars (Diphacinone) via the topical route by the patient. The individual handled bars of product and broke them up using his bare hands. It was unknown how long the individual handled the product and if he washed his hands afterwards. Approximately 8 hours post exposure, the individual developed a fever, nausea, body aches, shakiness, pain in the legs, leg cramps, difficulty sleeping, and facial twitching while sleeping. On approximately 01-Feb-2024, the individual developed talking in his sleep, rapid breathing, shallow breathing, and became incoherent. The individual was transported via ambulance to the emergency room. Upon exam, low blood pressure was noted (90/40). Unspecified labwork was performed that showed the kidneys were not function properly (renal insufficiency). The individual tested negative for the flu, RSV, and Covid. The individual was treated with acetaminophen and hydrocodone / acetaminophen for pain management and ondansetron for the nausea. The blood pressure returned to normal and the patient became coherent again. The individual was released from the emergency room and sent home. On 03-Feb-2024, the individual developed stomach pain. He was evaluated at an urgent care center where x-rays were performed and showed a distended stomach. The individual was referred to an emergency room. While at the emergency room they performed an unspecified scan and diagnosed him with diverticulitis and early stages of heart failure. The individual was treated with an unspecified antibiotic, prescribed antibiotics to continue at home, and discharged. The treating physician did not feel the signs were related to handling the rodenticide product. On approximately 04-Feb-2024, the individual developed dark stools and later that day began coughing up blood. The individual was taken back to the emergency room. A CT scan of the lungs was performed and the individual was diagnosed with pneumonia. Abnormal kidney, liver, and heart function were also noted but improving (as of 06-Feb-2023) since starting antibiotics for the pneumonia. On 07-Feb-2024, a bronchoscopy was performed and no bleeding was noted. The individual currently remained hospitalized receiving unspecified treatments. The clinical signs were improving. The treating physician advised the reporter (individual's wife) that the signs were not related to exposure to the rodenticide. No further information has been received.
Major
Assessment: Long acting anti-coagulants are not well absorbed into systemic circulation through the skin and the described short term dermal exposure is not expected to result in the reported signs and symptoms. The consumer has been diagnosed with diverticulitis, heart failure and pneumonia, in which his doctors believe are the cause of his signs and symptoms. The information provided by the reporter appears reliable and sufficient to confirm the product did not cause the reported adverse event.